Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MYCiMAX

Financiado

Cerrado

Maximizing the use of a first clinically viable MYC inhibitor

Even though the MYC oncogene is a most-wanted target in cancer therapy, no MYC inhibitor has yet reached clinical approval. The applicant has developed Omomyc, the first MYC-inhibiting mini-protein to have successfully completed a... ver más

30/04/2029

FUNDACIO PRIVADA I...

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCO... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 16M€

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-04-29

ERC-2023-ADG: ERC ADVANCED GRANTS Scope:Objectives

I+D

Cerrada hace 1 año

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

FUNDACIO PRIVADA INSTITUT D'...

2.50M€ | Lider

Proyectos interesantes

GBM-CPP

Medical Technol...

Biotechnology

148K€ Cerrado

Curtana

Medical Technol...

Pharmaceuticals

71K€ Cerrado

RTC-2016-5079-1

Medical Technol...

Biotechnology

841K€ Cerrado

RTC2019-007067-1

Medical Technol...

Biotechnology

1K€ Cerrado

MYCINHIBINCLINIC

Medical Technol...

Biotechnology

2M€ Cerrado

MYCure

Medical Technol...

Biotechnology

6M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 60 meses Fecha Inicio: 2024-04-29
Fecha Fin: 2029-04-30

Líder del proyecto

FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCO... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 16M€

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Even though the MYC oncogene is a most-wanted target in cancer therapy, no MYC inhibitor has yet reached clinical approval. The applicant has developed Omomyc, the first MYC-inhibiting mini-protein to have successfully completed a Phase Ia clinical trial. The goal of this proposal is to maximise the use of this compound, as both a therapeutic and study tool, opening new lines of research in different aspects of MYC biology. To start with, since Omomyc cannot efficiently cross the blood brain barrier, excluding it from use in brain malignancies or brain metastases, in Aim 1, we propose to validate its efficacy when delivered intracranially by different means, including osmotic pumps and hydrogels, as well as to test its delivery by intracarotid injection, in glioblastoma and brain metastases. Then, in Aim 2 and 3, we will explore its combination with personalized medicine, namely PARPi and KRASi, respectively. These 2 aims are derived from two pillars of MYC biology: its role in DNA damage response and the paradigm of oncogene cooperation. Aim 2 will allow us to shed light on the role of MYC in homologous recombination and resistance to PARPi, while Aim 3 will deliver on the molecular mechanisms underlying the cooperation of RAS and MYC in multiple tumour types, where their combined inhibition could represent an unprecedented therapeutic opportunity. Finally, Aim 4 will focus on the characterisation of cancers such as Small Cell Lung Cancer and Gastrointestinal Stromal Tumours that have the peculiarity of being defective for MAX – MYC’s natural partner – but that recapitulate a MYC-dependent tumour phenotype, likely driven by other members of the MYC network, whose function could also be hindered by Omomyc treatment. Notably, each of the aims explores new aspects of MYC biology, tracing new lines of research around the most deregulated oncogene in human tumours as well as having immediate translational applicability in upcoming clinical trials of Omomyc.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores